Cargando…
Challenges and Advances in Managing Thrombocytopenic Cancer Patients
Cancer patients have varying incidence, depth and duration of thrombocytopenia. The mainstay of managing severe chemotherapy-induced thrombocytopenia (CIT) in cancer is the use of platelet transfusions. While prophylactic platelet transfusions reduce the bleeding rate, multiple unmet needs remain, s...
Autores principales: | Leader, Avi, Hofstetter, Liron, Spectre, Galia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000983/ https://www.ncbi.nlm.nih.gov/pubmed/33799591 http://dx.doi.org/10.3390/jcm10061169 |
Ejemplares similares
-
Cancer‐associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study
por: Sharman Moser, Sarah, et al.
Publicado: (2022) -
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer
por: Falanga, Anna, et al.
Publicado: (2022) -
Arterial Thromboembolism in Patients With AF and CHA(2)DS(2)-VASc Score 0-2 With and Without Cancer
por: Leader, Avi, et al.
Publicado: (2023) -
Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study
por: Icht, Oded, et al.
Publicado: (2023) -
Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura
por: Bae, Sung Hwa, et al.
Publicado: (2022)